Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

201378 citationsJournal Article

Authors

Matthias Kopp · University of Lübeck

Eckard Hamelmann · St. Josef-Hospital

Meike Bendiks · Universitäres Kinderwunschzentrum Lübeck

Stefan Zielen · Goethe University Frankfurt

Wolfgang Kamin · Evangelisches Krankenhaus Hamm

Karl‐Christian Bergmann · Charité - Universitätsmedizin Berlin

Christian Klein

Abstract

Eighteen weeks' treatment of omalizumab in combination with SIT in patients with SAR and comorbid SAA reduced the symptom load during the treatment period but showed no prolonged effect during treatment with SIT only. A slight increase in lung function (FEV1) in patients formerly treated with the omalizumab/SIT combination therapy should encourage further evaluation of long-term effects of omalizumab.

Topics & Keywords

Allergic Rhinitis and Sensitization Asthma and respiratory diseases Dermatology and Skin Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Pediatric Allergy and Immunology

Volume 24, Issue 5, pp. 427-433

DOI: 10.1111/pai.12098

Field-Weighted Citation Impact: 5.39